Clinical Trials on Pre Menopausal Age in Czechia

Total 64 results

Novo Nordisk A/S

Completed

Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy

Menopause | Hormone Replacement Therapy, Post-Menopausal

Czech Republic
Rovi Pharmaceuticals Laboratories

Active, not recruiting

Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

Healthy

Czechia
Rovi Pharmaceuticals Laboratories

Recruiting

Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (LEILA-1)

Healthy

Czechia
Charles University, Czech Republic

Active, not recruiting

Changes in Brain Activity During Mirror Therapy and Virtual Reality Therapy

Healthy | Age of Probands 18 - 55 Years

Czechia
University Hospital Hradec Kralove

Unknown

Treatment of AMD With Rheohemapheresis /RHF/ (TARHF)

Age Related Macular Degeneration

Czech Republic
Allergan
Molecular Partners AG

Terminated

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Wet Age-Related Macular Degeneration

Switzerland, France, Czech Republic
General University Hospital, Prague
Charles University, Czech Republic; Institute of Hematology and Blood Transfusion...

Recruiting

Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia (PRIME)

Preterm Birth | Preeclampsia

Czechia
University Hospital Olomouc
Palacky University

Completed

Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome

Cataract | Age-related Cataract | Intraoperative Floppy Iris Syndrome | Adrenergic Receptor Antagonist Adverse Reaction

Czechia
Hoffmann-La Roche

Completed

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

Post-Menopausal Osteoporosis

United States, Germany, United Kingdom, Spain, Italy, Hungary, Belgium, Mexico, Poland, Denmark, France, Norway, Brazil, Czechia
Hoffmann-La Roche

Completed

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

Post Menopausal Osteoporosis

Australia, United Kingdom, United States, Brazil, Germany, South Africa, France, Spain, Switzerland, Italy, Canada, Hungary, Belgium, Mexico, Poland, Denmark, Norway, Czechia, Romania
Estetra
ICON Clinical Research

Active, not recruiting

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Vasomotor Symptoms | Menopausal Symptoms

Spain, United States, Argentina, Lithuania, Poland, Italy, Hungary, United Kingdom, Romania, Czechia, Brazil, Canada, Russian Federation, Slovakia
Pfizer

Completed

Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice

Age-related Macular Degeneration

Czechia
Sandoz

Terminated

Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age (SGA)

Short Children Born Small for Gestational Age (SGA)

Czechia, Germany, Hungary, Poland, Georgia, Romania
Hoffmann-La Roche

Completed

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Post Menopausal Osteoporosis

Spain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
Masaryk University
St. Anne's University Hospital Brno, Czech Republic

Not yet recruiting

Noninvasive Temporal Interference Stimulation: Modulating Associative Memory by Targeting Deep-brain Targets (Deep-HiPs)

Alzheimer Disease | Healthy Aging | Mild Cognitive Impairment | Memory Disorders in Old Age

Czechia
Hoffmann-La Roche

Completed

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

Post-Menopausal Osteoporosis

Spain, South Africa, Germany, Mexico, Italy, Belgium, United States, Poland, Denmark, Hungary, Czech Republic, France, Norway, United Kingdom, Australia
Sandoz

Completed

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Small for Gestational Age

Belgium, Czechia, Georgia, Hungary, Poland, Romania, Germany
Sylentis, S.A.

Recruiting

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Czechia, Slovakia, Poland
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
Pfizer

Completed

Genotropin Treatment In Very Young Children Born Small For Gestational Age (EGN)

Infant, Small for Gestational Age

Czech Republic, Spain, Sweden, Netherlands, Belgium, France, Germany, Italy, Switzerland
Bioeq GmbH

Completed

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (COLUMBUS-AMD)

Age-related Macular Degeneration (AMD)

France, Italy, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Ukraine, Austria, Czechia, Israel
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Bioeq GmbH

Completed

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

Neovascular Age-related Macular Degeneration

Bulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Menopause

Belgium, Finland, Sweden, South Africa, Croatia, United Kingdom, France, Romania, Ukraine, Spain, Poland, Hungary, Czech Republic, Mexico, Netherlands
Shanghai Henlius Biotech

Active, not recruiting

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

United States, Singapore, Spain, Germany, Slovakia, China, Hungary, Australia, Bulgaria, Poland, Latvia, Czechia, France, Italy, Serbia
Novo Nordisk A/S

Completed

Efficacy on Height in SGA Children Treated With Growth Hormone

Foetal Growth Problem | Small for Gestational Age

Israel, Spain, Sweden, Finland, Germany, Portugal, Czech Republic, Poland
PanOptica, Inc.

Completed

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, United Kingdom, Hungary, Latvia
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

United States, Switzerland, Canada, Poland, Italy, Germany, Portugal, Norway, Slovakia, Czechia
Masaryk University

Completed

Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring

Preeclampsia

Czech Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE)

Neovascular Age-related Macular Degeneration

Germany, Turkey, Austria, Canada, Czechia, United Kingdom, Hungary, Italy, Lithuania, Guatemala, France, Ireland, Argentina, Portugal, Spain, Sweden, Greece, Switzerland, Slovakia, Finland, Netherlands, Colombia, Mexico, Panama
Opthea Limited

Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-1)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

United States, Netherlands, Hungary, Italy, Czechia, Israel, Greece, Austria
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Opthea Limited

Recruiting

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Malaysia, Poland, Spain, Thailand, Ukraine, United Kingdom
Opthea Limited

Active, not recruiting

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Philippines and more
Bayer

Recruiting

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause (NIRVANA)

Sleep Disturbances Associated With Menopause

United States, Germany, Belgium, Czechia, Poland, Austria, Spain, Netherlands
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Spain, Germany, Croatia, Japan, United Kingdom, United States, Italy, Switzerland, France, Canada, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 (Skylight 2)

Hot Flashes

United States, Canada, Czechia, United Kingdom, Latvia, Poland, Spain
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause (Skylight 1)

Hot Flashes

United States, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause (Skylight 4)

Hot Flashes

United States, Czechia, Canada, Latvia, Poland, Spain, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland

Clinical Trials on Pre Menopausal Age in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations